Efficacy of Infliximab for Hidradenitis Suppurativa: Assessment of Clinical and Biological Inflammatory Markers
Maïa Delage, Mahtab Samimi, Michael Atlan, Laurent Machet, Gérard Lorette, Annabel Maruani

To cite this version:
Efficacy of Infliximab for Hidradenitis Suppurativa: Assessment of Clinical and Biological Inflammatory Markers

Maïa DELAGE¹, Mahtab SAMIMI¹, Michaël ATLAN², Laurent MACHET¹–³, Gérard LORETTE¹ and Annabel MARUANI¹,³
Departments of ¹Dermatology, ²Plastic Surgery and ³INSERM U930, University François Rabelais Tours, CHRU Tours, France

Hidradenitis suppurativa (HS) is a chronic, suppurative, cutaneous disease of areas of the body with apocrine glands. It can be physically debilitating and have a considerable effect on quality of life (1). It mainly affects women, usually starts in adolescence or shortly thereafter, and is promoted by smoking and obesity (2–5).

The usual treatments for HS, including topical antibiotics, zinc gluconate, orally administered antibiotics, isotretinoin, cyproterone acetate and surgical excision, are often unsatisfactory or induce only transitory improvement in severe cases (10). A few case reports, small series and one trial have indicated a certain efficiency of infliximab (11–23). Several other reports on this subject have been reviewed (24).

The primary objective of this study was to evaluate the efficacy of infliximab in seven patients with moderate to severe HS resistant to local and systemic treatments. The secondary objective was to determine whether inflammation blood test results were changed with infliximab.

METHODS

This retrospective study included all patients consecutively receiving infliximab for moderate to severe HS (Hurley score II–III) that was resistant to several local and at least two, 3-month-long systemic treatments in the dermatology department of the Hospital at Tours between 2006 and 2009.

Data were collected at inclusion on demographic information, disease duration, former treatments, initial severity of the disease as evaluated by the Hurley score, extent of disease, quality of life as estimated by the Dermatology Life Quality Index (DLQI), blood test measurements (C-reactive protein (CRP) level and neutrophil count) and side-effects. In May 2009, patients underwent re-testing, including by the DLQI and self-evaluation of improvement or aggravation (percentage of improvement globally, in pain and in seeping on a visual analogue scale, scores ranging from 0 to 100 mm). The principal outcome criterion was percentage improvement globally, in
seeping, in pain and in DLQI score as assessed by the patient. These data were expressed in medians and ranges. The secondary outcome criterion was change in both inflammation serum markers (CRP level > 10 mg/l and neutrophil count > 7,000/mm³ were regarded as abnormal values).

RESULTS

We included 7 patients (4 women), mean age 37 years. Their main features are shown in Table I. Patients had all previously received at least two general medications (antibiotics, isotretinoin, cyproterone acetate, zinc gluconate). The mean disease duration was 12 years. Patients had received a median of 6 perfusions (range 3–19) of infliximab, 5 mg/kg, at weeks 0, 2, and 6 and then every 8 weeks. The mean follow-up was 72 weeks. The Hurley score was II for six patients and III for one patient. The initial median DLQI score was 18 (range 10–19).

Improvement in DLQI was noted in 6 of 7 patients, with a median DLQI score variation of 10 (range 0–15). The final median score was 8 (range 0–18) (Table II). Six of seven patients noted global improvement, with no aggravation. The median change was 70% for global improvement, 70% for pain, and 70% for DLQI score (Table II).

Adverse effects were observed in two patients, one with an eczema-like eruption after 3 perfusions, which led to treatment interruption, and one with a pretragian abscess, which occurred after three perfusions, after which treatment was stopped.

We found no significant changes in inflammatory blood marker values. The median CRP level was 6 mg/l (range 1–93 mg/l) before treatment and 5 mg/l (range 1–131 mg/l) after treatment. The median neutrophil count was 8.2 × 10³/mm³ (range 5.3–12.9 × 10³/mm³) before treatment and 4.9 × 10³/mm³ (range 4.5–12.8 × 10³/mm³) after treatment (Table II).

DISCUSSION

This open study of seven cases of moderate to severe HS resistant to other treatment demonstrates the efficacy of infliximab as judged by symptoms and improvement of DLQI. Adverse events were mild to moderate. Inflammatory markers (CRP and neutrophils) were not significantly changed with treatment, and are probably not good measures of the efficacy of infliximab.

Infliximab is a chimerical human/mouse antibody that links with great affinity to the soluble and transmembrane forms of tumour necrosis factor α (TNFα) and inhibits its functional activity. It is also used for rheumatoid arthritis, Crohn’s disease, spondylarthritis, psoriasis and psoriatic arthritis. When used to treat Crohn’s disease, infliximab reduces local tissue levels of TNFα, decreases the inflammatory cell infiltrates and lowers the level of interleukin 6. Patients receiving infliximab for rheumatoid arthritis showed lowered inflammatory blood values. Infliximab was efficient for HS associated with Crohn’s disease. Various case reports showed infliximab efficient for treating HS alone (19–21, for review see 24).

One report described the efficacy of infliximab according to Sartorius score and tolerance in 7 patients (19); 5 patients showed improvement after 6 weeks, but only 2 of 5 after 10 weeks. The tolerance was considered mediocre, with one occurrence of colon cancer, an allergic reaction and one multifocal motor neuropathy. A second retrospective trial of 5 patients studied disease activity after 5 months’ treatment (20). The improvement was quick and significant, with few side-effects. Another trial of 6 patients during 6 months showed good efficacy with few side-effects (21). In one trial, 9 of 15 patients showed 25–50% improvement and 4 showed more than 50% improvement (23). Of 75 patients in the literature, 65 showed at least moderate improvement with therapy (24).

As HS is a suppurative disease, initially sterile but quickly colonized by various bacteria, and with an increased risk of squamous cell carcinoma, infliximab must be used with care, with a regular clinical examination and precise recommendations to the patient and the general practitioner (25).

Two patients showed high inflammatory blood test values (CRP and neutrophils) at inclusion, without infection. Values for the other blood markers were close to normal. Thus, we were not able to study the treatment efficacy of infliximab on reducing values of inflammatory blood markers. This criterion was seldom used in other studies. Mekkes et al. (22) showed a decrease in CRP level in patients with HS after one perfusion of infliximab. Our study suggests that CRP is not a good

<table>
<thead>
<tr>
<th>Patient/age/sex</th>
<th>Disease duration (years)</th>
<th>Previous treatments</th>
<th>Affected areas</th>
<th>Hurley stages</th>
<th>Infliximab infusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/47/F</td>
<td>25</td>
<td>Cyproterone acetate, zinc gluconate</td>
<td>Axilla, inguinal folds, perianal</td>
<td>II</td>
<td>6</td>
</tr>
<tr>
<td>2/45/M</td>
<td>24</td>
<td>Antibiotics, isotretinoin, zinc gluconate</td>
<td>Axilla, inguinal folds, perianal</td>
<td>III</td>
<td>5</td>
</tr>
<tr>
<td>3/45/F</td>
<td>7</td>
<td>Antibiotics, zinc gluconate</td>
<td>Axilla, inguinal folds, gluteal areas</td>
<td>II</td>
<td>19</td>
</tr>
<tr>
<td>4/22/F</td>
<td>3</td>
<td>Antibiotics, zinc gluconate</td>
<td>Inguinal folds, perianal, perineum</td>
<td>II</td>
<td>14</td>
</tr>
<tr>
<td>5/29/M</td>
<td>11</td>
<td>Antibiotics, isotretinoin, zinc gluconate</td>
<td>Axilla, inguinal folds, perineum, cervical</td>
<td>II</td>
<td>3</td>
</tr>
<tr>
<td>6/34/M</td>
<td>8</td>
<td>Antibiotics, isotretinoin, zinc gluconate</td>
<td>Inguinal folds, perineum</td>
<td>II</td>
<td>6</td>
</tr>
<tr>
<td>7/36/F</td>
<td>6</td>
<td>Antibiotics, zinc gluconate</td>
<td>Inguinal folds, gluteal areas</td>
<td>II</td>
<td>3</td>
</tr>
</tbody>
</table>
clinical marker of infliximab efficacy for HS. According to Matusiak et al., the serum level of interleukin 2 receptor, although not used in routine practice, may associate better with disease activity (26).

The authors declare no conflict of interest.

REFERENCES